hantaviru
infect
caus
sever
emerg
diseas
human
associ
high
mortal
rate
therefor
becom
global
public
health
concern
previou
studi
show
tcell
epitop
fvvpillka
hantaan
viru
htnv
nucleoprotein
np
restrict
human
leukocyt
antigen
hla
induc
specif
tcell
respons
control
htnv
infect
human
howev
vivo
immunogen
peptid
effect
tcell
immun
remain
unclear
base
detail
structur
analysi
peptid
complex
function
investig
use
b
transgen
tg
mice
found
overal
structur
peptid
complex
display
typic
mhc
class
fold
primari
anchor
residu
secondari
anchor
residu
allow
peptid
bind
tightli
hlaa
molecul
residu
middl
portion
peptid
extrud
bind
groov
may
site
allow
recognit
tcell
receptor
immun
peptid
b
tg
mice
induc
cytotox
tcell
respons
character
induct
high
express
level
tumor
necrosi
granzym
b
htnv
challeng
trial
signific
reduct
level
antigen
htnv
rna
load
observ
liver
spleen
kidney
tg
mice
prevaccin
peptid
thu
find
highlight
abil
htnv
epitopespecif
tcell
immun
control
htnv
support
possibl
htnvnp
peptid
natur
process
vivo
hlaa
manner
may
good
candid
develop
htnv
peptid
vaccin
hantaviru
infect
caus
sever
emerg
diseas
human
associ
high
mortal
rate
therefor
becom
global
public
health
concern
previou
studi
show
tcell
epitop
fvvpillka
hantaan
viru
htnv
nucleoprotein
np
restrict
human
leukocyt
antigen
hla
induc
specif
tcell
respons
control
htnv
infect
human
howev
vivo
immunogen
peptid
effect
tcell
immun
remain
unclear
base
detail
structur
analysi
peptid
complex
function
investig
use
b
transgen
tg
mice
found
overal
structur
peptid
complex
display
typic
mhc
class
fold
primari
anchor
residu
secondari
anchor
residu
allow
peptid
bind
tightli
hlaa
molecul
residu
middl
portion
peptid
extrud
bind
groov
may
site
allow
recognit
tcell
receptor
immun
peptid
b
tg
mice
induc
cytotox
tcell
respons
character
induct
high
express
level
tumor
necrosi
granzym
b
htnv
challeng
trial
signific
reduct
level
antigen
htnv
rna
load
observ
liver
spleen
kidney
tg
mice
prevaccin
peptid
thu
find
highlight
abil
htnv
epitopespecif
tcell
immun
control
htnv
support
possibl
htnvnp
peptid
natur
process
vivo
hlaa
manner
may
good
candid
develop
htnv
peptid
vaccin
tcell
immun
hantaan
viru
frontier
immunolog
wwwfrontiersinorg
august
volum
articl
introduct
widespread
emerg
zoonot
pathogen
hantavirus
belong
bunyavirida
famili
signific
grow
impact
global
public
health
murineborn
hantaviru
transmiss
caus
case
annual
human
diseas
worldwid
signific
portion
world
popul
risk
infect
hantavirus
hantaan
viru
htnv
asia
dobrava
viru
puumala
viru
puuv
europ
seoul
viru
worldwid
lead
hemorrhag
fever
renal
syndrom
hfr
human
hantavirus
sin
nombr
viru
snv
and
viru
andv
north
south
america
directli
caus
human
hantaviru
pulmonari
syndrom
hp
infect
serotyp
lead
broad
spectrum
outcom
rang
asymptomat
infect
acut
fever
hemorrhag
even
lifethreaten
shock
acut
kidney
lung
injuri
china
total
hfr
case
death
report
year
casefat
rate
high
total
global
hfr
case
aros
china
caus
infect
htnv
strain
prototyp
member
hantaviru
famili
us
base
center
diseas
control
prevent
report
total
hp
case
year
reach
higher
casefat
rate
therebi
rais
concern
world
health
organ
situat
exacerb
period
emerg
novel
speci
hantavirus
lead
disrupt
healthcar
system
epidem
area
major
health
concern
worldwid
although
live
attenu
inact
vaccin
use
part
world
partial
prevent
hantavirus
infect
remain
urgent
need
effect
therapeut
prophylact
vaccin
better
control
epidem
situat
negativesens
rna
genom
encod
two
structur
protein
nucleocapsid
protein
np
envelop
glycoprotein
give
rise
primari
antigen
htnv
htnvnp
demonstr
highli
immunogen
conserv
respons
vigor
cellular
humor
immun
respons
heterodim
matur
htnv
glycoprotein
gn
gc
consid
main
sourc
neutral
antibodi
product
human
suggest
immunolog
mechan
viral
clearanc
relat
close
tcellmedi
immun
respons
notion
support
evid
hantavirusspecif
cell
play
critic
role
control
viru
infect
previou
result
demonstr
tcell
respons
acut
stage
hfr
patient
character
vigor
cytotox
cell
ctl
respons
multifunct
helper
th
cell
respons
htnv
infect
patient
milder
sever
hfr
typic
mount
vigor
htnvspecif
tcell
respons
direct
epitop
htnv
wherea
patient
sever
critic
hfr
tend
weak
narrowli
focus
tcell
respons
moreov
also
report
cell
specif
immunodomin
epitop
htnvnp
epitop
fvvpillka
restrict
human
leukocyt
antigen
hla
display
polyfunct
activ
includ
cytotox
activ
abil
prolifer
abil
produc
effector
cytokin
find
neg
correl
htnvnp
epitopeprim
tcell
respons
diseas
sever
suggest
least
partial
control
htnv
infect
hfr
patient
although
genom
viru
could
potenti
encod
multitud
tcell
epitop
specif
tcell
respons
viral
infect
often
focus
epitop
known
immunodomin
hlaa
htnvnp
epitop
previous
identifi
immunodomin
epitop
also
highli
conserv
epitop
concord
among
hantavirus
compar
sequenc
serotyp
studi
respons
induc
hlaa
htnvnp
epitop
previous
use
peptidehla
phla
pentam
detect
frequenc
htnvnp
epitopespecif
cell
peripher
blood
mononuclear
cell
pbmc
hlaa
hfr
patient
encount
tcell
receptor
tcr
phla
appear
key
factor
immunogen
potenti
tcell
respons
structur
studi
examin
phla
highli
relev
understand
cellular
immun
respons
htnv
infect
xray
crystal
structur
could
reveal
structur
close
conform
peptidehla
complex
howev
crystal
structur
demonstr
interact
htnv
epitop
hla
molecul
analyz
date
hlaa
preval
hla
class
allel
among
chines
han
popul
consid
associ
control
mani
viral
infect
wellestablish
hlaa
htnvnp
epitop
elicit
highli
effect
tcell
respons
associ
reduc
serum
viru
load
hfr
individu
howev
remain
unclear
whether
htnvnp
epitop
induc
strong
tcell
immun
htnv
infect
vivo
human
mice
mice
engraft
human
tissu
andor
engin
express
human
gene
consid
power
tool
studi
speciesrestrict
pathogen
induc
vivo
human
immun
therefor
human
b
transgen
tg
mous
model
express
chimer
monochain
hlaa
infect
htnv
would
ideal
viru
replic
model
explor
effect
vivo
respons
prime
epitop
studi
htnvnp
peptidespecif
respons
b
tg
mice
may
provid
opportun
understand
vivo
mechan
htnvspecif
cell
viru
replic
immunoprophylaxi
htnv
infect
inact
htnv
vaccin
provid
free
vaccin
hfr
highrisk
popul
china
decad
epidemiolog
survey
reveal
feasibl
safeti
immunogen
inact
vaccin
howev
efficaci
vaccin
improv
reduc
risk
infect
peptid
vivo
may
mimic
epitop
present
restrict
mhc
target
cell
thu
induc
relev
immun
respons
therefor
develop
peptid
vaccin
may
better
method
specif
direct
cellular
immun
system
pathogen
given
critic
role
htnvnp
epitop
induc
protect
tcell
respons
epitop
may
appeal
target
peptid
vaccin
develop
howev
although
htnvnp
peptid
present
hlaa
well
character
vitro
phla
interact
may
directli
correl
efficaci
peptid
vaccin
effect
htnvnp
epitop
mice
challeng
htnv
remain
larg
unclear
identifi
mechan
critic
design
effect
htnv
peptid
vaccin
collect
result
studi
illustr
interact
htnvnp
peptid
hlaa
molecul
demonstr
vaccin
b
tg
mice
abl
control
htnv
challeng
upon
induct
effect
cellular
immun
respons
htnv
htnvnp
peptid
identifi
immunogen
epitop
natur
process
vivo
hlaa
manner
find
provid
crucial
inform
better
evalu
tcell
immun
htnv
infect
may
import
implic
diagnosi
immunotarget
hfr
may
help
guid
develop
safe
effect
tcellbas
htnv
peptid
vaccin
human
studi
perform
strict
accord
recommend
guid
care
use
laboratori
anim
nation
health
medic
research
council
china
protocol
approv
committe
ethic
anim
experi
fourth
militari
medic
univers
licens
number
procedur
perform
sodium
pentobarbit
anesthesia
everi
effort
made
minim
anim
suffer
htnv
strain
kindli
provid
depart
microbiolog
univers
commerci
hfr
inactiv
vaccin
youerjian
zhejiang
tianyuan
biopharmaceut
co
ltd
china
deriv
mixtur
htnv
seov
provid
bival
purifi
hfr
vaccin
base
epitop
identifi
previous
peptid
htnvnp
fvvpillka
restrict
hlaa
peptid
htnvnp
vpillkali
restrict
hlab
synthes
puriti
assess
highperform
liquid
chromatographi
mass
spectroscopi
cl
bioscientif
xian
china
peptid
resuspend
steril
phosphatebuff
salin
pb
solut
mm
store
aliquot
use
lymphoblast
cell
line
design
cem
purchas
american
type
cultur
collect
cat
manassa
va
usa
cell
line
transporterassoci
antigen
process
tap
defici
express
hlaa
cell
cultur
rpmi
cultur
medium
contain
fetal
bovin
serum
gibco
grand
island
ny
usa
uml
penicillin
mgml
streptomycin
cellbind
assay
perform
describ
elsewher
determin
bind
capabl
synthet
peptid
hlaa
molecul
briefli
cell
incub
peptid
human
sigma
serumfre
rpmi
medium
h
express
hlaa
cell
determin
stain
fluorescein
isothiocyan
fitc
label
monoclon
antibodi
mab
biolegend
detect
flow
cytometri
facscan
bd
bioscienc
result
present
fluoresc
index
fi
determin
follow
fi
mean
pe
fluoresc
given
peptid
mean
pe
fluoresc
without
peptid
mean
pe
fluoresc
without
peptid
fi
repres
highaffin
peptid
indic
peptid
stabli
combin
hlaa
molecul
surfac
cell
increas
mean
fluoresc
hlaa
molecul
least
onefold
refold
htnvnpderiv
peptid
hlaa
heavi
chain
perform
describ
previous
briefli
hlaa
heavi
chain
extracellular
domain
express
inclus
bodi
escherichia
coli
use
pet
prokaryot
express
system
novagen
inc
inclus
bodi
separ
dissolv
solut
mm
trishcl
ph
urea
hlaa
heavi
chain
peptid
subsequ
mix
molecular
ratio
refold
buffer
mm
trishcl
mm
largininehcl
mm
edta
mm
oxid
glutathion
mm
reduc
glutathion
sigma
incub
h
solubl
refold
complex
concentr
use
bicinchonin
acid
bca
protein
assay
pierc
purifi
gel
filtrat
follow
anion
exchang
chromatographi
use
superdex
amersham
pharmacia
biotech
ensur
correctli
refold
phla
complex
final
complex
concentr
mgml
mm
trishcl
ph
mm
nacl
crystal
xray
crystallographi
data
collect
structur
determin
crystal
screen
initi
use
commerci
kit
hampton
research
crystal
obtain
vapordiffus
hang
drop
contain
equal
volum
protein
mg
ml
mm
nmorpholino
ethanesulfon
acid
me
ph
polyethylen
glycol
mm
me
ph
plate
incub
k
examin
h
week
diffract
crystal
soak
reservoir
solut
supplement
glycerol
cryoprotect
flashcool
maintain
k
cryostream
obtain
subsequ
microseed
data
collect
rigaku
raxi
iv
imag
plate
use
rigaku
micromax
rotationanod
xray
inhous
gener
rigaku
oper
kv
cu
data
process
scale
use
hkl
research
inc
immun
b
tg
mice
peptid
b
tg
mice
divid
four
group
n
immun
tg
mice
peptid
carri
use
ntermin
fragment
murin
glycoprotein
adjuv
briefli
male
b
tg
mous
immun
via
subcutan
inject
multipl
site
hlaa
peptid
emulsifi
complet
incomplet
freund
adjuv
difco
ntermin
fragment
murin
inject
volum
adjust
anim
three
immun
inject
administ
mous
interv
week
method
use
immun
hlab
epitop
uncorrel
peptid
control
group
subcutan
inject
hfr
inactiv
vaccin
pb
use
posit
neg
control
group
respect
ten
day
last
immun
splenocyt
isol
erylys
specif
cytokineproduc
cell
detect
via
enzymelink
immunospot
elispot
assay
intracellular
stain
preliminari
experi
conduct
determin
infect
htnv
strain
naiv
b
tg
mice
follow
htnv
challeng
ten
day
final
immun
booster
mice
challeng
htnv
strain
intramuscular
inject
pfumous
tg
mice
sacrif
day
follow
htnv
challeng
tissu
sampl
includ
cerebrum
heart
liver
spleen
lung
kidney
weigh
prepar
gram
millilit
tissu
suspens
pb
tissu
sampl
freezethaw
three
time
grind
centrifug
rpm
min
collect
supernat
tissu
determin
immunogen
htnvnp
peptid
vivo
perform
use
interferon
ifn
elispot
assay
mabtech
deutschland
germani
previous
describ
briefli
splenocyt
obtain
b
tg
mice
place
duplic
elispot
plate
cellswel
stimul
overnight
peptid
cell
phytohemagglutinin
pha
sigmaaldrich
st
loui
mo
usa
peptid
stimul
serv
posit
background
control
respect
spot
form
deposit
enzym
substrat
count
use
elispot
plate
reader
cellular
technolog
limit
usa
adjust
spotform
cell
sfc
subtract
averag
neg
valu
express
splenocyt
posit
respons
defin
least
input
cell
exceed
three
time
background
respons
subtract
number
spot
background
control
stimul
sampl
splenocyt
unstimul
control
well
never
exceed
five
spot
per
well
intracellular
cytokin
stain
degranul
assay
splenocyt
obtain
b
tg
mice
immun
restimul
peptid
previous
describ
briefli
brefeldin
sigmaaldrich
st
loui
mo
costimulatori
molecul
clone
clone
ml
biolegend
ad
cultur
h
antibodi
bd
pharmingen
ad
well
stimul
cell
stimul
phorbol
myrist
acet
pma
sigmaaldrich
st
loui
mo
usa
ionomycin
sigmaaldrich
st
loui
mo
usa
medium
alon
use
posit
neg
control
respect
cell
label
antimous
antimous
mab
bd
bioscienc
pharmingen
fix
permeabil
use
bd
cytofixcytoperm
kit
bd
bioscienc
pharmingen
stain
pe
apclabel
pelabel
antitumor
necrosi
factor
tnf
fitclabel
antigranzym
b
pelabel
mab
bd
bioscienc
pharmingen
fitc
pe
apcconjug
mous
use
isotyp
control
stain
total
event
per
sampl
collect
use
facscalibur
flow
cytomet
bd
bioscienc
analysi
perform
immedi
flowjo
version
treestar
splenocyt
defin
fscssc
cell
defin
event
display
dot
plot
versu
cytokin
cytokin
respons
consid
posit
percentag
cytokin
greater
background
subtract
hantaan
viru
antigen
supernat
major
tissu
tg
mice
detect
sandwich
enzymelink
immunosorb
assay
elisa
antihtnvnp
mab
prepar
depart
microbiolog
univers
mab
horseradish
peroxidaseconjug
use
coat
detect
antibodi
respect
normal
tissu
supernat
use
neg
control
absorb
measur
wavelength
nm
use
standard
elisa
plate
reader
bior
valu
exceed
neg
control
pn
consid
posit
result
major
organ
includ
heart
liver
spleen
lung
kidney
brain
postexposur
tg
mice
preserv
nonfrozen
tissu
rna
preserv
solut
solarbio
cn
tissu
rna
organ
extract
use
rna
purif
extract
kit
tiangen
biotech
cn
use
templat
revers
transcript
use
rtpcr
kit
takara
obtain
cdna
target
sequenc
htnv
segment
detect
major
organ
use
sybr
realtim
quantif
pcr
kit
takara
follow
primer
htnv
forward
htnv
revers
mous
gapdh
forward
mous
gapdh
revers
result
record
cycl
time
ct
quantifi
statist
analys
graph
perform
use
spss
spss
inc
chicago
il
usa
prism
softwar
version
graphpad
la
jolla
ca
usa
frequenc
cell
cytokin
secret
present
median
rang
valu
wilcoxon
ranksum
test
use
paramet
comparison
two
subject
group
twotail
pvalu
p
consid
statist
signific
htnv
strain
nucleoprotein
genbank
access
number
hantavirus
use
studi
correspond
htnv
strain
structur
glmwlsyfv
hlaa
deposit
protein
data
bank
access
number
pdb
code
synthes
htnvnp
peptid
exhibit
high
bind
affin
hlaa
molecul
previou
find
show
htnvnp
peptid
restrict
hlaa
induc
effect
tcell
respons
hfr
patient
investig
bind
affin
peptid
hlaa
molecul
cellpeptidebind
assay
conduct
synthes
peptid
increas
surfac
express
hlaa
molecul
correspond
fi
valu
indic
peptid
high
affin
bind
hlaa
molecul
wherea
hlab
peptid
vpillkali
htnvnp
use
neg
control
show
fi
indic
bind
hlaa
figur
moreov
hlaa
complex
refold
assay
show
predict
molecular
weight
protein
come
ml
elut
buffer
would
kda
coincid
molecular
mass
phla
complex
figur
figur
supplementari
materi
therefor
result
suggest
confirm
htnvnp
peptid
typic
hlaa
epitop
crystal
structur
peptid
bound
hlaa
analyz
crystal
trial
carri
purifi
heterodim
heavi
chain
express
e
coli
synthes
cognat
peptid
refold
diffract
crystal
phla
obtain
figur
supplementari
materi
expect
overal
threedimension
structur
domain
arrang
complex
show
typic
mhc
class
fold
exactli
similar
formerli
determin
peptidehlaa
molecul
figur
specif
antiparallel
helic
extracellular
region
hlaa
heavi
chain
form
antigen
peptidebind
groov
support
eightstrand
bedplat
domain
occupi
standard
posit
bedplat
figur
compar
previous
determin
hlaa
complex
peptid
glmwlsyfv
pdb
code
structur
superposit
similar
hlaa
low
root
mean
squar
differ
rmsd
amino
acid
sequenc
align
reveal
main
chain
conform
quit
similar
figur
c
specif
residu
act
primari
anchor
residu
peptid
perform
conform
peptid
residu
val
posit
nterminu
residu
ctermin
peptid
deepli
buri
pocket
indic
typic
anchor
residu
figur
particular
interest
residu
point
side
chain
pocket
might
act
secondari
anchor
residu
peptid
bind
hlaa
howev
might
secondari
anchor
peptid
figur
although
differ
residu
observ
peptid
crystal
structur
reveal
two
peptid
adopt
similar
conform
bind
hlaa
molecul
anchor
residu
help
peptid
tightli
bind
hlaa
heavi
chain
enhanc
stabil
entir
complex
also
import
note
central
locat
residu
main
chain
peptid
tend
protrud
antigenbind
groov
side
chain
expos
residu
point
upward
hlaa
surfac
indic
amino
acid
probabl
recognit
site
tcr
might
involv
tcr
dock
figur
mutant
posit
may
influenc
antigen
peptid
even
lead
immun
escap
viru
unambigu
electron
densiti
complex
observ
bound
peptid
well
defin
insid
peptidebind
groov
hlaa
figur
structur
properti
complex
may
relat
immunogen
epitop
allow
induc
specif
immun
respons
htnv
infect
vivo
induct
peptidespecif
cell
b
tg
mice
immun
htnvnp
peptid
defin
structur
complex
htnvnp
peptidehlaa
molecul
next
sought
determin
vivo
immunogen
potenti
peptid
valid
abil
elicit
specif
tcell
respons
vitro
previou
studi
group
b
tg
mice
immun
inject
peptid
htnvnp
peptid
htnvnp
htnv
inactiv
vaccin
pb
describ
section
materi
method
three
round
vivo
stimul
splenocyt
prime
mice
first
test
product
via
elispot
assay
peptid
stimul
result
show
larg
number
cell
tg
mice
inocul
peptid
demonstr
strong
product
median
magnitud
rang
splenocyt
even
higher
secret
level
detect
posit
control
group
inject
htnv
inactiv
vaccin
median
rang
splenocyt
although
differ
statist
signific
contrast
specif
tcell
reactiv
detect
splenocyt
gener
tg
mice
inject
pb
median
rang
splenocyt
figur
importantli
although
immun
peptid
tg
mice
effici
elicit
tcell
respons
hlab
htnvnp
peptid
use
uncorrel
peptid
control
unabl
prime
ineffici
prime
obviou
tcell
respons
tg
mice
median
valu
rang
splenocyt
product
figur
notabl
compar
tg
mice
inject
pb
sfc
count
index
tcell
reactiv
increas
approxim
eightfold
peptideimmun
mice
p
figur
moreov
comparison
secret
peptid
group
uncorrel
peptid
control
group
reveal
signific
quantit
differ
magnitud
peptid
tcell
respons
immun
peptid
elicit
significantli
stronger
produc
tcell
respons
observ
tg
mice
inocul
peptid
p
figur
result
indic
htnvnp
peptid
natur
process
vivo
hlaa
manner
induc
robust
tcell
respons
b
tg
mice
htnvnp
peptid
elicit
high
level
cytokin
cytotox
mediat
product
defin
phenotyp
cell
precis
splenocyt
group
b
tg
mice
directli
stimul
ex
vivo
peptid
number
cell
show
specif
induc
cytokin
secret
cytotox
mediat
express
assess
via
intracellular
stain
analysi
repres
analys
distinct
pattern
stain
shown
figur
overal
cell
splenocyt
tg
mice
immun
display
cytokin
cytotox
mediat
product
predominantli
character
granzym
b
secret
express
upon
stimul
peptid
consist
detect
elispot
assay
mark
high
frequenc
primari
cytokin
induc
splenocyt
tg
mice
immun
peptid
median
rang
cell
high
frequenc
cell
also
observ
peptid
mice
median
rang
cell
figur
analysi
reveal
cell
display
adequ
cytolyt
capac
appear
highli
function
secret
cytolyt
effector
granzym
b
median
rang
cell
upregul
express
median
rang
cell
stimul
peptid
figur
interestingli
similar
observ
ex
vivo
comparison
product
cell
mice
display
trend
toward
higher
level
cytokin
product
cytolyt
mediat
express
secret
cell
control
group
shown
figur
tg
mice
inject
pb
use
neg
control
detect
cell
express
cytokin
cytolyt
mediat
frequenc
cell
express
cytokin
cytolyt
mediat
significantli
lower
frequenc
induc
group
p
p
p
granzym
b
p
percentag
median
rang
cell
median
rang
cell
granzym
b
median
rang
cell
produc
cell
posit
control
group
inocul
htnv
inactiv
vaccin
slightli
lower
frequenc
stimul
group
although
differ
signific
howev
higher
frequenc
express
observ
cell
tg
mice
immun
peptid
mice
immun
htnvinactiv
vaccin
median
rang
cell
p
importantli
compar
substanti
higher
frequenc
cytokin
secret
cytolyt
mediat
express
specif
cell
peptid
tg
mice
tg
mice
inocul
hlab
peptid
show
much
less
median
rang
cell
p
median
rang
cell
p
granzym
b
median
rang
cell
p
product
express
median
rang
cell
p
confirm
specif
hlapeptid
interact
induc
effect
tcell
respons
given
granzym
b
releas
consid
quantit
indic
cytotox
activ
cell
observ
indic
ctl
signific
upregul
granzym
b
express
might
possess
cytotox
capac
directli
kill
htnvinfect
cell
immun
htnvnp
peptid
reduc
htnv
titer
tissu
supernat
demonstr
htnvnp
could
elicit
high
level
specif
tcell
respons
tg
mice
conduct
htnv
challeng
experi
determin
whether
peptid
tcell
respons
could
defend
htnv
infect
vivo
thu
use
vaccin
candid
purpos
establish
model
htnv
infect
base
replic
viru
vivo
k
b
tg
mice
tg
mice
group
immun
subsequ
challeng
administr
htnv
strain
day
immun
tissu
sampl
cerebrum
heart
liver
spleen
lung
kidney
tg
mice
harvest
mous
day
postchalleng
detect
htnv
titer
preliminari
measur
viremia
six
organ
htnvinfect
tg
mice
show
high
level
htnv
antigen
could
detect
liver
spleen
kidney
lung
cerebrum
heart
tg
mice
suggest
liver
spleen
kidney
major
organ
infect
replic
htnv
b
tg
mice
figur
supplementari
materi
consist
preliminari
analys
detect
viru
found
lung
cerebrum
heart
four
group
immun
tg
mice
htnv
challeng
htnv
antigen
tissu
supernat
detect
via
elisa
figur
expect
htnv
challeng
tg
mous
neg
control
group
inject
pb
display
evid
hightit
htnv
replic
tissu
supernat
liver
spleen
kidney
wherea
signific
reduct
mean
viral
titer
observ
organ
mice
immun
htnv
inact
vaccin
figur
importantli
prior
immun
peptid
led
signific
decreas
htnv
titer
supernat
liver
spleen
kidney
mean
viral
titer
compar
neg
control
tg
mice
p
liver
p
spleen
p
kidney
figur
howev
immun
irrelev
control
peptid
htnvnp
show
still
high
level
htnv
titer
supernat
liver
spleen
kidney
tg
mice
markedli
higher
mice
follow
htnv
challeng
p
liver
p
spleen
p
kidney
figur
notabl
although
peptid
immun
signific
decreas
htnv
antigen
titer
tg
mice
reduct
level
found
liver
spleen
kidney
immun
tg
mice
figur
indic
effici
tcell
respons
induc
peptid
comprehens
inhibit
viru
replic
clear
htnv
therefor
protect
htnv
infect
b
tg
mice
immun
htnvnp
peptid
inhibit
htnv
replic
b
tg
mice
protect
htnv
challeng
result
show
htnvnp
peptidespecif
tcell
respons
decreas
htnv
titer
tissu
supernat
htnvinfect
tg
mice
confirm
follow
htnv
rna
load
analysi
organ
tg
mice
htnv
challeng
sensit
accur
assay
realtim
pcr
specif
htnv
segment
carri
determin
htnv
rna
load
isol
organ
peptideimmun
mice
challeng
htnv
shown
figur
htnv
rna
lung
cerebrum
heart
detect
b
transgen
mice
divid
four
group
n
accord
differ
immun
includ
mice
immun
hlaa
htnvnp
peptid
fvvpillka
hlab
htnvnp
peptid
vpillkali
htnv
vaccin
pb
respect
ten
day
final
immun
booster
mice
challeng
htnv
strain
sacrif
day
follow
htnv
challeng
htnv
antigen
yaxi
detect
lung
liver
cerebrum
spleen
kidney
heart
xaxi
b
transgen
mice
htnv
infect
four
group
respect
detect
viru
found
lung
cerebrum
heart
four
group
immun
transgen
mice
htnv
challeng
detect
via
elisa
b
comparison
htnv
antigen
level
yaxi
tissu
supernat
liver
spleen
kidney
immun
group
xaxi
c
comparison
htnv
antigen
level
yaxi
hlaa
htnvnp
peptid
mice
group
hlab
htnvnp
peptid
mice
group
pbsinject
mice
group
xaxi
organ
liver
spleen
kidney
respect
result
shown
repres
three
independ
experi
pn
ratio
consid
posit
wilcoxon
ranksum
test
use
statist
evalu
ns
signific
realtim
pcr
howev
detect
signific
differ
htnv
rna
load
tg
mice
receiv
peptid
inocul
mice
immun
control
peptid
inject
pb
accord
result
htnv
antigen
detect
significantli
lower
level
htnv
rna
load
observ
liver
spleen
kidney
tg
mice
immun
peptid
neg
control
mice
p
liver
p
spleen
p
kidney
figur
mice
immun
irrelev
control
peptid
htnvnp
show
markedli
higher
level
htnv
rna
load
liver
spleen
mice
p
liver
p
spleen
figur
wherea
signific
differ
observ
htnv
rna
load
kidney
peptidetr
mice
mice
figur
although
inhibitori
tendenc
htnv
rna
load
peptid
immun
group
still
observ
kidney
notabl
capac
peptid
immun
reduc
htnv
rna
load
compar
among
differ
organ
tg
mice
htnv
rna
load
liver
lower
spleen
p
kidney
p
figur
indic
may
tissu
specif
peptid
tcell
respons
inhibit
htnv
replic
togeth
data
clearli
suggest
inhibit
htnv
replic
liver
spleen
kidney
tg
mice
mediat
tcell
respons
b
transgen
mice
divid
four
group
n
includ
mice
immun
hlaa
htnvnp
peptid
fvvpillka
hlab
htnvnp
peptid
vpillkali
htnv
vaccin
pb
respect
ten
day
final
immun
booster
mice
challeng
htnv
strain
sacrif
day
follow
htnv
challeng
detect
htnv
rna
load
yaxi
lung
liver
cerebrum
spleen
kidney
heart
xaxi
b
transgen
mice
htnv
challeng
four
group
comparison
htnv
rna
load
could
detect
liver
spleen
kidney
immun
transgen
mice
htnv
challeng
among
four
immun
mice
group
b
htnv
rna
load
yaxi
liver
spleen
kidney
immun
group
xaxi
comparison
htnv
rna
load
liver
spleen
liver
kidney
hlaa
htnvnp
peptid
mice
group
result
shown
record
cycl
time
ct
quantifi
repres
three
independ
experi
wilcoxon
ranksum
test
use
statist
evalu
ns
signific
prevent
infecti
diseas
use
therapeut
prophylact
vaccin
success
method
direct
immun
system
specif
pathogen
peptid
vaccin
greater
efficaci
pathogen
would
bring
major
improv
protect
popul
infect
previou
find
tcell
respons
import
compon
natur
acquir
immun
control
htnv
infect
provid
foundat
develop
htnv
peptid
vaccin
may
combat
htnv
effici
induc
specif
tcell
immun
studi
report
htnvnp
peptid
could
immunogen
epitop
determin
base
bind
hlaa
molecul
vivo
function
valid
provid
evid
immun
peptid
b
tg
mice
success
gener
reactiv
cell
respons
inhibit
htnv
infect
htnv
challeng
suggest
peptid
may
good
candid
use
design
htnv
peptid
vaccin
inactiv
vaccin
htnv
asia
prove
boost
humor
respons
howev
titer
htnvspecif
neutral
antibodi
suffici
high
popul
therefor
expect
abl
effectu
limit
htnv
amplif
complet
prevent
infect
concert
drive
develop
peptid
vaccin
efficaci
induc
htnvdirect
tcell
immun
previou
evid
illustr
feasibl
safeti
immunogen
peptid
vaccin
howev
due
mhc
restrict
low
immunogen
broad
applic
peptid
vaccin
diseas
may
current
limit
sever
studi
variou
clinic
applic
peptid
vaccin
suggest
mani
potenti
variabl
type
length
peptid
load
one
multipl
peptid
antigenpres
cell
apc
rout
administr
may
attribut
design
effici
peptid
vaccin
select
right
epitop
first
crucial
step
design
effect
vaccin
number
method
propos
identif
tcell
epitop
base
bind
abil
predictor
peptid
mhc
molecul
report
previous
multipl
hla
class
irestrict
ctl
epitop
htnvnp
identifi
use
overlap
peptid
map
screen
method
hfr
patient
one
peptid
restrict
hlaa
find
also
show
htnvnp
epitop
could
prime
specif
tcell
respons
hlaa
hfr
patient
intriguingli
patient
higher
level
tcell
respons
epitop
maintain
mild
moder
hfr
sever
notabl
hlaa
allelerestrict
epitop
suggest
studi
potenti
immunogen
chines
han
popul
hlaa
allel
predomin
high
henc
studi
select
htnvnp
peptid
evalu
potenti
immunogen
use
candid
peptid
vaccin
design
thu
investig
structur
featur
hlaa
electron
densiti
peptid
bound
hlaa
unambigu
high
qualiti
overal
structur
phla
complex
allow
detail
discuss
bind
characterist
crystal
structur
analysi
offer
opportun
determin
whether
bind
site
hlaa
interact
one
anoth
thereaft
evalu
bind
affin
peptid
hlaa
molecul
gener
peptid
among
mhc
class
molecul
usual
consid
aa
long
contain
anchor
residu
prefer
mhc
allel
exact
local
anchor
residu
peptid
reli
specif
mhc
allel
whether
anchor
residu
stabli
interact
mhc
allelespecif
pocket
key
determin
evalu
affin
peptidemhc
pmhc
molecul
particular
residu
posit
n
termini
residu
c
termini
known
primari
anchor
posit
bind
peptid
hlaa
molecul
residu
posit
common
secondari
anchor
peptidehlaa
complex
provid
accur
analysi
phla
templat
peptid
taken
directli
cocrystal
xray
structur
pdb
code
use
homolog
structur
model
viral
phla
complex
result
reveal
gener
conform
posit
within
peptidebind
groov
hlaa
similar
structur
observ
peptid
contain
optim
hlaa
motif
val
anchor
posit
ala
ctermin
anchor
posit
howev
peptid
bound
hlaa
molecul
via
residu
val
posit
leu
posit
secondari
anchor
residu
appear
emin
featur
peptid
despit
observ
structur
differ
two
peptid
bind
site
side
chain
residu
occupi
ident
posit
complex
act
secondari
anchor
residu
thu
peptid
fit
well
bind
groov
form
interfac
phla
stabl
interact
peptid
anchor
residu
hlaa
molecul
could
improv
bind
affin
complex
may
affect
immunodomin
peptidespecif
ctl
respons
report
previous
biophys
structur
landscap
pmhc
complex
play
critic
role
tcr
select
flexibl
peptid
mhc
groov
might
affect
respond
tcr
repertoir
report
middl
portion
peptid
residu
extrud
mhc
bind
groov
may
predominantli
contribut
interact
tcr
indic
complex
may
ordinari
properti
cellsurfac
ligand
recognit
cell
multipl
mechan
propos
tcr
pmhc
recognit
bind
peptid
need
present
viralinfect
cell
mhc
molecul
suffici
express
level
form
stabl
synaps
antigenpres
cell
effector
cell
high
tcr
pmhc
affin
appear
decis
factor
tcell
immunogen
potenti
necessari
specif
cell
complet
clear
virus
publish
studi
kinet
releas
rate
tcr
pmhc
complex
found
often
correl
tcell
activ
complex
structur
determin
impli
major
contact
tcr
peptid
might
central
hydrophob
residu
viral
peptid
thu
specul
strong
antivir
efficaci
ctl
respons
induc
might
primarili
deriv
favor
hydrophob
interplay
central
peptid
residu
correspond
hydrophob
residu
complementarydetermin
region
cdr
loop
tcr
howev
given
tcrpeptid
recognit
mainli
determin
highli
flexibl
variabl
cdr
loop
tcr
tcrpmhc
complex
easili
extrapol
therefor
definit
structur
affin
peptid
interact
phla
complex
fulli
elucid
requir
studi
futur
also
noteworthi
function
valid
perform
ultim
determin
immunogen
tcell
epitop
structur
analys
valid
examin
immunogen
antivir
efficaci
peptid
b
tg
mice
import
note
peptid
elicit
effect
ctl
respons
must
first
success
present
mhc
class
molecul
peptid
administ
mice
mimick
epitop
present
target
cell
associ
restrict
mhc
molecul
thu
capabl
induc
relev
immun
respons
present
studi
vaccin
hlaa
htnvnp
peptid
induc
tcell
respons
b
tg
mice
wherea
hlab
htnvnp
peptid
vaccin
gener
rel
poor
overal
reactiv
htnv
challeng
trial
signific
reduct
htnv
antigen
level
rna
load
htnv
b
tg
mice
vaccin
htnvnp
peptid
compar
unvaccin
tg
mice
compar
hlab
peptidevaccin
group
find
indic
respons
could
infer
due
presenc
ctl
could
propos
evid
natur
recognit
peptid
vivo
moreov
examin
compar
respons
hlaa
hlab
peptid
tg
mice
identifi
peptid
could
process
present
classic
hlaa
manner
prime
boost
specif
ctl
respons
control
htnv
infect
vivo
result
import
select
antigen
target
appli
vaccin
design
induc
protect
tcell
respons
addit
compar
extern
glycoprotein
htnv
conserv
htnvnp
antigen
among
differ
subtyp
deriv
hantavirus
gener
high
thu
htnvnp
epitop
highli
immunogen
human
might
also
potent
immunogen
capabl
induc
tcell
respons
htnv
infect
tg
mice
combin
high
conserv
make
ideal
candid
develop
novel
peptid
vaccin
although
antigenspecif
product
often
use
biomark
viru
infect
possibl
addit
cytokin
might
allow
specif
qualit
differ
detect
immun
respons
viru
infect
character
cellular
immun
respons
specif
htnvnp
peptid
addit
cytokin
cytotox
mediat
test
splenocyt
immun
tg
mice
ex
vivo
stimul
peptid
consist
data
obtain
elispot
assay
immun
induc
high
percentag
product
cell
proinflammatori
cytokin
produc
mani
type
immunocyt
enhanc
respons
promot
ctl
activ
drive
antivir
immun
mice
immun
peptid
increas
express
observ
expect
secret
granzym
b
express
primarili
induc
activ
ctl
also
observ
higher
extent
tg
mice
suggest
htnvnp
peptidespecif
cell
own
strong
cytolyt
capac
htnv
infect
rapid
product
granul
cell
import
defens
htnv
infect
similar
result
observ
tg
mice
use
htnvinactiv
vaccin
immun
case
percentag
cytokineor
cytotox
mediatorproduc
cell
significantli
higher
wherea
peptid
tg
mice
detect
cell
express
cytokin
indic
peptid
present
requir
match
context
hla
class
molecul
notabl
b
tg
mous
model
shown
suitabl
identif
human
hlaa
tcell
epitop
use
studi
htnv
challeng
experi
peptid
protect
htnv
inact
vaccin
similar
level
tcell
respons
observ
follow
vaccin
regimen
suggest
peptid
immun
protect
achiev
mice
model
howev
may
disadvantag
tg
mous
model
htnv
challeng
mice
consid
natur
reservoir
htnv
develop
diseas
symptom
therefor
could
evalu
antiviru
effect
peptid
ctl
respons
via
reduct
elimin
diseas
symptom
paramet
select
assess
protect
measur
viral
load
major
organ
tg
mice
quantif
htnv
gene
express
encod
np
realtim
rtpcr
detect
htnv
antigen
via
elisa
organ
mice
follow
htnv
challeng
shown
good
method
evalu
htnv
viral
load
mice
base
peak
viru
replic
chose
day
postchalleng
detect
result
indic
immun
b
tg
mice
peptid
follow
htnv
challeng
inhibit
htnv
replic
enhanc
clearanc
htnv
liver
spleen
kidney
mice
tg
mice
group
immun
peptid
comparison
show
htnv
rna
load
liver
slightli
lower
spleen
kidney
accord
result
found
tg
mice
inject
pb
indic
even
without
preimmun
htnv
infect
may
vari
among
tissu
tg
mice
fact
differ
express
tissueselect
home
lymphocyt
receptor
site
antigen
exposur
differ
tissuespecif
apc
may
lead
differ
outcom
induct
cell
impact
sequenti
antigenspecif
respons
summari
structur
featur
htnvnp
peptidehlaa
molecul
complex
analyz
studi
far
know
first
report
crystal
structur
htnvnp
ctl
epitop
upon
interact
hla
molecul
confirm
htnvnp
peptid
highli
immunogen
epitop
restrict
hlaa
challeng
b
tg
mice
htnv
vivo
reveal
vivo
immunogen
htnvnp
peptid
antivir
effici
ctl
respons
import
find
present
indic
htnvnp
peptid
high
efficaci
immunogen
induc
protect
immun
use
regimen
peptid
vaccin
design
observ
provid
structur
function
insight
regard
tcellmedi
antivir
immun
htnv
infect
may
import
implic
hfr
immunotherapi
htnv
peptid
vaccin
develop
howev
relationship
bind
function
peptidespecif
ctl
unknown
followup
studi
bind
affin
hlaa
specif
tcr
measur
determin
tcr
interact
cognat
phla
activ
cell
induc
ctl
respons
studi
conceiv
experi
design
bj
ym
fz
experi
perform
ym
lfc
data
analyz
interpret
ym
lfc
bj
fz
yusiz
cz
yunz
kt
rz
contribut
reagent
materi
analysi
tool
ym
draft
paper
lc
ky
bj
fz
critic
revis
manuscript
import
intellectu
content
